Results

Total Results: 1,187 records

Showing results for "week".

41. Cer-265-Radiation-Bone-Disease-App-F (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-app-f.xlsx
    January 01, 2019 - Title Appendix F. Quality Assessments Margaret: Margaret: Make Assessments in title plural to match overall appendix file. Please give each table a number and title--Table G-1 annd so on. Table F-1. RCT QA Table F-1. Quality assessments for randomized controlled trials evaluating external b…

42. Digestible Carbohydrate Intake and Maternal-Infant Outcomes: Appendix D Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-appendix-d.xlsx
    January 01, 2019 - -20, 26-28, 35-37 weeks gestation and 7 days postpartum; birth FFQ (147-item); intake asked by day, week … 5) vs. 69.5 (5) BMI, mean kg/m2 (SD): 27.7 (1.3) vs. 27.6 (1.2) Gestational age at enrollment, mean week … food diary and weight; dietary intake vs. vomiting captured during first trimester; GWG captured last week … Family history diabetes: 26% vs. 27% (From Callaway 2019): Daily probiotic vs. placebo from gestational week … Quintile 5 vs. quintile 1 vs. quintile 2 vs. quintile 3 vs. quintile 4 Rate of weight gain, mean kg/week

43. Carbohydrate-Intake-Prepub-Final-Research-Table-Da (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-prepub-final-research-table-da.xlsx
    January 01, 2019 - -20, 26-28, 35-37 weeks gestation and 7 days postpartum; birth FFQ (147-item); intake asked by day, week … 5) vs. 69.5 (5) BMI, mean kg/m2 (SD): 27.7 (1.3) vs. 27.6 (1.2) Gestational age at enrollment, mean week … food diary and weight; dietary intake vs. vomiting captured during first trimester; GWG captured last week … Family history diabetes: 26% vs. 27% (From Callaway 2019): Daily probiotic vs. placebo from gestational week … Quintile 5 vs. quintile 1 vs. quintile 2 vs. quintile 3 vs. quintile 4 Rate of weight gain, mean kg/week

44. Cer-250-Cannabis-2024-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-table-e5.xlsx
    January 01, 2024 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … B Pain intensity index (VAS 0-100 scale) mean relative change (improvement) rates at week 24 83.4% vs … B Pain-related disabilities (VAS 0-100 scale) mean relative change (improvement) rates at week 24 76.0% … B Physical quality of life (VR12-PCS; NRS 100 scale) mean relative change (improvement) rates at week … Anxiety (DASS-A; NRS21) mean relative change (improvement) rates at week 24 78.4% vs. 52.3%, p<0.001

45. Preterm-Birth-Terbutaline-Pump Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/preterm-birth-terbutaline-pump_surveillance.pdf
    January 30, 2013 - (cycle 1) but using different search dates for MEDLINE (Oct 1, 2010 to Nov 9, 2012), EMBASE (2011 Week … 1 to 2012 Week 44), Cochrane Library (2011-2012), CINAHL (Published from: September 1st 2011 to November … ed. (2141186) 32 30 and 31 (0) *************************** Database: Embase <1980 to 2012 Week

46. Preterm-Birth-Terbutaline-Pump Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_surveillance.pdf
    January 30, 2013 - (cycle 1) but using different search dates for MEDLINE (Oct 1, 2010 to Nov 9, 2012), EMBASE (2011 Week … 1 to 2012 Week 44), Cochrane Library (2011-2012), CINAHL (Published from: September 1st 2011 to November … ed. (2141186) 32 30 and 31 (0) *************************** Database: Embase <1980 to 2012 Week

47. Back-Pain-Imaging Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/back-pain-imaging_clinician.pdf
    April 01, 2016 - Secondary patient-reported outcomes included average back pain intensity in the past week, average … leg pain intensity in the past week, pain interference with activities, depression and anxiety, health

48. A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/glucocorticoid-injections_clinician.pdf
    June 01, 2016 - A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis: A Brief Summary of Findings for Clinicians KEY CLINICAL ISSUE What are the relative effectiveness and adverse effect…

49. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
    January 01, 2025 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … B Pain intensity index (VAS 0-100 scale) mean relative change (improvement) rates at week 24 83.4% vs … B Pain-related disabilities (VAS 0-100 scale) mean relative change (improvement) rates at week 24 76.0% … B Physical quality of life (VR12-PCS; NRS 100 scale) mean relative change (improvement) rates at week … Anxiety (DASS-A; NRS21) mean relative change (improvement) rates at week 24 78.4% vs. 52.3%, p<0.001

50. Hepatitis-C Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_executive.pdf
    November 01, 2012 - three times a week with standard interferon).13 Dual therapy with pegylated interferon plus ribavirin … of patients with genotype 2 or 3 infection with a rapid virologic response (undetectable HCV-RNA by week … The regimen with 8 weeks of telaprevir was associated with a slightly lower SVR rate than the 12 week … One other trial of 24-week fixed duration triple therapy with telaprevir, pegylated interferon alfa … Among patients randomized to the 24-week telaprevir regimen, one to two- thirds experienced a rash (

51. Urinary-Incontinence-Treatment Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_surveillance.pdf
    October 29, 2012 - incontinence episodes per day, n(%) was significantly lower in darifenacin group versus placebo at week … incontinence episodes per day, n(%) was significantly lower in darifenacin group versus placebo at week … Placebo Mean change from baseline at 12 week in daily UI episodes (Mean± SD): -3.0 ±2.8 vs. … BT (n= 41; dose:NA) 20 Week PFMT vs. … PFMT IG (n=17; two, 1hour sessions per week) vs. CG (n=15; no sessions) GT vs.

52. Cer-238-Cervical-Ripening-Appendix-E-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-1.xlsx
    January 01, 2009 - -During the following week the patient was managed without any variation on the basis of her participation … -Patients received the same medication each week. … During subsequent examination, if the Bishop score totaled 8 or the patient reached the forty-second week … During subsequent examination, if the Bishop score totaled 8 or the patient reached the forty-second week … If a second dose of the study drug was administered at week 40, then FHR monitoring was only completed

53. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - JIA, refractory to infliximib and standard immunosuppressive therapy ACR Pedi 30 response at week … 24 96 weeks At week 24, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 50%, and 40%. … By week 96, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 93%, and 93% of 25 patients. … 12 and 100%, 94.1%, 88.2%, 64.7% at week 48. … Mean disease activity score remained below the remission level (2.6) from week 24.

54. Juvenile-Arthritis-Dmards Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
    March 14, 2013 - JIA, refractory to infliximib and standard immunosuppressive therapy ACR Pedi 30 response at week … 24 96 weeks At week 24, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 50%, and 40%. … By week 96, ACR Pedi 30, 50, and 70 responses were achieved by 98%, 93%, and 93% of 25 patients. … 12 and 100%, 94.1%, 88.2%, 64.7% at week 48. … Mean disease activity score remained below the remission level (2.6) from week 24.

55. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
    February 01, 2015 - review products by timeframe Timeframe (number of products) Scope End-Users Purpose Within 1 week … , payers Policy; coverage decisions; purchasing decisions 7 Production Time: Within 1 Week … Five products from five organizations were completed within 1 week (up to 5 days). … to completion ranged from 5 minutes (computer algorithm in which user enters query) to “less than 1 week … For example, the most rapid products (within 1 week) generally: searched a limited number of databases

56. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - reported for secukinumab 75 mg (57.5%), 150 3 mg (62.5%), and placebo (63.5%) groups up to week … 24 and the effect was maintained through week 52. … Serious adverse events were reported in 3.3% and 2.0% of patients, respectively, up to week 16.36 … Novartis Pharmaceuticals. 16 week efficacy and 2 year long term safety and efficacy of secukinumab … Novartis Pharmaceuticals. 16 week efficacy and 5 year long term efficacy, safety and tolerability

57. CER 215 Executive Summary: Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-215-depression-older-adults-executive-summary.pdf
    March 01, 2019 - Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized

58. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd-disposition-120104.pdf
    April 01, 2011 - They are approved for the symptom of frequent heartburn only up to 2 week courses x 3 in a year.” … I do note that their cutoff date was week 2 of 2010, but the Medline search target was extended to … As noted in the Methods section, they only searched in MedLine for randomized controlled trials to week … We request that it be included for the following reasons: 1- This was an 8 week healing study, not a … Healing of EE - Two multicenter, double-blind, randomized, active- controlled, 8-week trials evaluated

59. Cannabis-App-F1-F4-Tables-Surveillance-Report-2 0 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f1-f4-tables-surveillance-report-2_0_0.xlsx
    May 29, 2025 - , then 1 mg for 3 weeks, then a 1 week washout period followed by a 4 week placebo period Endpoint dose … of 1 mg per day 4 weeks of placebo, 1 week washout period, Nabilone 0.5 mg for one week, then 1 mg for … , then 1 mg for 3 weeks, then a 1 week washout period followed by a 4 week placebo period 4 weeks of … placebo, 1 week washout period, Nabilone 0.5 mg for one week, then 1 mg for three weeks NA NA 4 Short … , then 1 mg for 3 weeks, then a 1 week washout period followed by a 4 week placebo period 4 weeks of

60. Type-2-Diabetes-Medications-Update Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
    December 31, 2013 - At week 52, intervention resulted in greater Bosi, alogliptin (25 pioglitazone (15 with an HbA1c >= … A week 80 decrease of 3.37 kg in the metformin group and an increase of 1.42 kg in the Avandamet group … HDL cholesterol increased and triglycerides decreased from baseline to week 80 in both groups with … Total cholesterol and LDL cholesterol decreased from baseline to week 80 in the metformin group. … Increases in body weight from baseline were observed in both treatment groups at week 54: 4.8 and 4.1